Study identifies a new key factor contributing to aggressive nature of pancreatic cancer

The Pivotal Role of Galectin-1 in Pancreatic Cancer’s Aggressive Nature

Pancreatic cancer remains one of the most formidable foes in oncology, with a dire five-year survival rate of just 10%. Recent breakthroughs have highlighted the tumor microenvironment, especially the stroma, as a significant factor in the cancer’s aggressiveness. This dense network of proteins and non-tumor cells, including fibroblasts, fosters tumor growth and drug resistance. A groundbreaking study from teams at the Hospital del Mar Research Institute and Mayo Clinic, among others, has unveiled a new frontier in the fight against pancreatic cancer: the role of Galectin-1 within fibroblast nuclei.

Unveiling Galectin-1’s Hidden Role

Traditionally, fibroblasts were known for secreting Galectin-1, a protein implicated in promoting tumor growth. However, the recent study reveals that Galectin-1 also resides in the nuclei of fibroblasts, where it orchestrates a complex program of gene expression regulation without altering DNA sequences. This epigenetic influence includes the significant regulation of the KRAS gene, a notorious driver of pancreatic tumor aggression observed in 90% of patients.

New Horizons in Cancer Treatment Strategies

Understanding Galectin-1’s dual role ushers in a revolutionary approach to designing cancer therapies. “Until now, strategies revolved around blocking Galectin-1 in stroma. Now, the focus extends to inhibiting this protein within fibroblast nuclei, calling for innovative inhibitors,” explains Dr. Neus Martínez-Bosch from the Hospital del Mar Research Institute.

This research involved analyzing pancreatic cancer patient tissue samples and working with human fibroblast cell lines to probe the effects of blocking Galectin-1 and the KRAS gene, culminating in the deactivation of pro-tumor cells.

Future Trends: Therapeutic Possibilities and Challenges

The discovery of Galectin-1’s nuclear function opens exciting therapeutic avenues, suggesting a multipronged inhibition approach to combat pancreatic cancer effectively. Such strategies could integrate inhibitors acting both externally on the stroma and internally within fibroblasts. Galectin-1 also contributes to blood vessel formation and immunotherapy resistance, indicating a broader scope for these inhibitors in cancer treatment.

Embracing a Collaborative Approach

The study underscores the importance of collaborative research. Contributions from the Pathology Department at Hospital del Mar and various CIBER (CIBERONC) researchers highlight how diverse expertise accelerates advancements. Collaboration across institutions not only refines understanding but also paves the path for nuanced multi-faceted treatment strategies.

Real-World Impact and Ongoing Research

Current efforts focus on pharmacological advancements to create potent Galectin-1 inhibitors. The ongoing studies aim to discover combinations that inhibit both extracellular and intracellular Galectin-1, potentially revolutionizing therapeutic approaches.

Frequently Asked Questions

How does Galectin-1 contribute to pancreatic cancer?

By residing in fibroblast nuclei, Galectin-1 controls gene expression, particularly the KRAS gene, which drives tumor growth and aggression. Additionally, it aids in stromal support for tumor development.

What are the potential future treatments based on this discovery?

Future treatments may involve special inhibitors targeting Galectin-1 both outside and inside fibroblast nuclei, addressing various cancer-promoting pathways. This includes limiting blood vessel formation and overcoming immunotherapy resistance.

Isn’t Galectin-1 involved in other diseases?

Yes, Galectin-1 plays roles in many biological processes and is implicated in other diseases as well, making understanding its function crucial beyond just cancer therapy.